From Yahoo Finance: 2025-06-23 01:37:00

Exact Sciences Corporation (NASDAQ:EXAS) is recognized as one of the 11 Best Genomics Stocks to Buy According to Hedge Funds. The company has shared new data from the Beta-CORRECT study confirming the effectiveness of its Oncodetect™ test for monitoring recurrence in stage II-IV colorectal cancer.

The study presented at ASCO 2025 showed that patients with ctDNA-positive results post-therapy and during surveillance had a significantly higher risk of recurrence. Exact Sciences plans to introduce a next-generation test in 2026 using Broad Institute’s MAESTRO technology to track patient-specific variations and detect ctDNA levels below 1 part per million.

Oncodetect, designed for molecular residual disease identification, has shown better prognosis prediction in stage III colorectal cancer compared to standard methods in both Alpha- and Beta-CORRECT trials. The updated version with whole-genome sequencing from the Broad Institute aims to enhance precision oncology through ctDNA-based advances.

While Exact Sciences (NASDAQ:EXAS) shows promise as an investment, some believe other AI stocks offer greater potential with less risk. For a potentially undervalued AI stock poised to benefit from current trends, consider exploring the best short-term AI stock. No disclosures were mentioned in the article.



Read more at Yahoo Finance: Exact Sciences Expands Oncodetect Validation, Unveils MRD Innovation Roadmap.